SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-23-101247
Filing Date
2023-09-15
Accepted
2023-09-15 16:56:22
Documents
1
Group Members
ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLCATLAS VENTURE ASSOCIATES X, L.P.ATLAS VENTURE ASSOCIATES X, LLCATLAS VENTURE OPPORTUNITY FUND I, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tm2326270d1_sc13da.htm SC 13D/A 118720
  Complete submission text file 0001104659-23-101247.txt   120641
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund X, L.P. (Filed by) CIK: 0001628098 (see all company filings)

IRS No.: 472435989 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Dianthus Therapeutics, Inc. /DE/ (Subject) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90538 | Film No.: 231259321
SIC: 2834 Pharmaceutical Preparations